Clinical trial
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With…
NCT00082836 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00082836 |
|---|---|
| Title | Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma |
| Official title | A Pilot Study of Radiolabeled Indium-111 and Yttrium-90 Ibritumomab Tiuxetan in Primary CNS Lymphoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Radiation |
| Interventions | rituximab, yttrium Y 90 ibritumomab tiuxetan |
| Enrollment | 10 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2007 |
| First posted | May 19, 2004 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: